A Glimpse Into The Expert Outlook On Iovance Biotherapeutics Through 4 Analysts
Ratings for Iovance Biotherapeutics (NASDAQ:IOVA) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 0 | 4 | 0 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 2 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 0 | 1 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.75, a high estimate of $11.00, and a low estimate of $5.00. Observing a downward trend, the current average is 18.42% lower than the prior average price target of $9.50.
Diving into Analyst Ratings: An In-Depth Exploration
The standing of Iovance Biotherapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Reni J. Benjamin | Citizens | Announces | Market Outperform | $5.00 | - |
| Etzer Darout | Barclays | Raises | Overweight | $11.00 | $10.00 |
| Reni J. Benjamin | Citizens | Announces | Market Outperform | $5.00 | - |
| Etzer Darout | Barclays | Raises | Overweight | $10.00 | $9.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Iovance Biotherapeutics. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Iovance Biotherapeutics compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Iovance Biotherapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Iovance Biotherapeutics's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on Iovance Biotherapeutics analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Get to Know Iovance Biotherapeutics Better
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.
Iovance Biotherapeutics: Financial Performance Dissected
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Iovance Biotherapeutics's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 15.2% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Iovance Biotherapeutics's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -135.28% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Iovance Biotherapeutics's ROE stands out, surpassing industry averages. With an impressive ROE of -13.03%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Iovance Biotherapeutics's ROA excels beyond industry benchmarks, reaching -10.07%. This signifies efficient management of assets and strong financial health.
Debt Management: With a below-average debt-to-equity ratio of 0.07, Iovance Biotherapeutics adopts a prudent financial strategy, indicating a balanced approach to debt management.
Understanding the Relevance of Analyst Ratings
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
This article was generated by Benzinga's automated content engine and reviewed by an editor.